Theme: Inspiring Innovations and Interactive discussions on Blood Cancer

Blood Cancer 2017

Blood Cancer 2017

Conference Series LLC is glad to welcome all the interested participants to its 8th International Conference on Blood Cancer and Treatment during June 26-27, 2017 at London, UK. The conference will be organized around the theme “Advanced Practices in Blood Cancer Treatment”. Blood Cancer 2017 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it.

Blood Cancer 2017 will be an initiative to find the weapon to fight against the dreadful blood cancers, to protect and save lives. Discussions will be focused on the different types of blood cancers, possibility of early detection and treatment at the advanced stages of these cancers to prolong life.

Track 1Blood Malignancies

Blood malignancies are forms of cancer that begins in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are acute and chronic leukaemia, lymphomas, multiple myeloma and myelodysplastic syndromes. Myeloproliferative neoplasms, or MPNs, are hematologic cancers that arise from malignant hematopoietic myeloid progenitor cells in the bone marrow, such as the precursor cells of red cells, platelets and granulocytes. The other types of Blood Malignancies also include sarcoma, lymphodema, Non-Hodgkin lymphoma (NHL) and lymphoma, lymphoid cancer, bone marrow cancer.

 

Track 2: Leukemia

Leukemia is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Different kinds of leukemia are believed to have different causes. There are four main types of leukemia — acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).Leukemias and lymphomas both belong to a broader group of tumors that affect the blood, bone marrow, and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues. It is the most common type of cancer in children, with three quarters of leukemia cases in children being ALL

 

Track 3: Myeloma

Myeloma is a cancer arising from plasma cells, a type of white blood cell which is made in the bone marrow. Unlike many cancers, myeloma does not exist as a lump or tumour. Myeloma can be of smoldering type & the common known as multiple myeloma. Myeloma affects multiple places in the body (hence ‘multiple’ myeloma) where bone marrow is normally active in an adult i.e. within the bones of the spine, skull, pelvis, the rib cage, long bones of the arms and legs and the areas around the shoulders and hips. Myeloma is a relapsing-remitting cancer.

 

Track 4: Myelodysplastic Syndrome

The myelodysplastic syndromes (also known as MDS or myelodysplasia) are haematological medical conditions with ineffective production of all blood cells. In some cases, the disease worsens and the patient develops low blood counts caused by progressive bone marrow failure. The myelodysplastic syndromes are all disorders of the hematopoietic stem cells in the bone marrow. In MDS, blood production is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production. In this section detailed information about myelodysplastic syndromes will be discussed.

 

Track 5: Childhood Hematological Cancers

Childhood blood cancers are rare. The major subtypes of childhood blood cancers are lymphoblastic, Burkitt, large B cell & anaplastic large cell. Treatment at special centres for children and teens provides the advantages of specialized care. In addition, childhood cancers tend to respond to treatment better than adult cancers do, and children's bodies often tolerate treatment better. Treatment may involve antibiotics, blood transfusions, or other measures to fight infection. In this section, we will be discussing about the various types of childhood blood cancers, symptoms included, their diagnosis & treatment options available.

Track 6: Blood Cancer: Diagnosis

To confirm the presence of cancer and the severity or the stages of the cancer various cancer detection tests are carried out; certain cancer blood tests or other laboratory tests, such as an analysis of your urine or a biopsy of a suspicious area, to help guide the diagnosis. With the exception of blood cancers, blood tests generally can't absolutely tell cancer or some other noncancerous condition, but they can give your doctor the clues about what's going on inside the body. The other kind of tests performed to diagnose or confirm blood cancer can also include complete blood count and Blood protein testing, Tumour marker tests and Biopsy, Cytogenetic, Imaging and Radiation Oncology, Endoscopy.

 

Track 7: Blood Cancer : Causes & Symptoms

The cause is usually different from other types of cancer. Experts say that Blood Malignancies arise due to different causes, some of them are suspected and some are yet to be. It is nearly impossible to prove what caused a blood cancer in any individual, because most blood cancers have multiple possible causes.

Discussions will be carried out on the suspecting and suspected causes of blood cancer that include: Exposure to radiation and chemicals, Genetic predisposition, drugs, Human T-cell Leukemia Virus (HTLV), Electromagnetic energy, Genetic factors (chromosomal abnormalities, maternal fetal transmission (rare).

 

Track 8: Blood Cancer: Staging

Staging is the process of determining the extent to which a cancer has developed by spreading. Contemporary practice is to assign a number from I-IV to a blood cancer, with I being an isolated cancer and IV being a cancer which has spread to the limit of what the assessment measures. The stage generally takes into account the size of a tumor, whether it has invaded adjacent organs, how many regions it has spread to, and whether it has appeared in more distant locations .There are different yards sticks to distinguish blood cancer into different stages according to the symptoms of prognosis and rate of metastasis. In this section discussions will be carried out on different stages of various blood cancers.

 

Track 9: Blood Cancer: Treatment and Care

Treatment depends on many factors, including the type of cancer; age; how fast the cancer is progressing; where the cancer has spread; the symptoms and other health conditions. According to one of the most recent findings, researchers have come up with a curative alternative to blood cancer. The medication seeks to block the release of irregular enzymes accountable for the metastasis of blood cancer that are various therapies. Surfeit of protein accountable for the enlargement and increase of cancerous cells are likely to be blocked as well by the researched medication.

Different types of therapies such as Biological Therapy, Chemotherapy, Radiation Therapy, Bone Marrow Transplantation,
Stem Cell Transplantation, Targeted Therapy, Watchful Waiting,  Clinical medicine and anticancer drugs, Gene therapy and Stem cells therapy will be discussed in this scientific session.

 

Track 10: Bone Marrow Transplantation & Surgery

A bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. A biopsy is a sample of tissue taken from the body in order to examine it more closely. A doctor should recommend a biopsy when an initial test suggests that an area of tissue in the body isn't normal. Doctors may call that area of abnormal tissue a lesion, a tumour, or a mass.Topics of discussion in the scientific sessions are Bone Marrow Surgery, Stem Cell Surgery, Hematopoietic Cell Transplantations

 

Track 11:  Immunology of Blood Cancer

Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumour marker-based diagnostic tests. These scientific sessions will include the discussion on various topics such as Immunotherapeutic approaches, immune tolerance and deficiencies, Anti-Blood Cancer Factor and immunotherapy.

 

Track 12: Blood Oncology

Many Advanced approaches to treat patients with blood cancer. Developments in personalized treatment are taken into account the type, location, and stage of the disease as well as the patient's age and physical health. Chemotherapy is the primary treatment for blood cancer, though some patients receive radiation therapy as well and/or a transplant of stem cells or bone marrow. According to studies, antioxidants like lymohotoxins can also reduce the risk of one suffering from Blood Malignancies.

Major discussions will be carried out on Molecular Pathogenesis and Personalized Treatment, Epidemiology of Blood Cancer ,Blood Cancer Awareness and Society, Alternate Cancer therapy, Prevention of blood cancer, Importance of Antioxidants.      

 

Track 13: Hematological Malignancies: Prognosis

The estimate of how the disease will go for a patient is called prognosis. There are many factors affect prognosis that include: the type of cancer and where it is in the body, the stage of the cancer, the cancer’s grade. Grade provides clues about how quickly the cancer is likely to grow and spread certain traits of the cancer cells, the age and how healthy body was before cancer & how successful is the treatment.

 

Track 14: Blood Cancer : Other Aspects

Other features that are related to blood cancer include several other factors. Anaemia is a common side effect of chemotherapy procedures & sometimes blood cancer itself is cause of anaemia. Researches have shown that there is a clear connection between blood cancer and thrombosis, because some of the genetic changes that cause blood cancer also increase the activation of clotting factors. People with cancer are at increased risk of developing these dangerous blood clots. The other risk factors include blood transfusions, lymphatic System defects, exposure to radiation and carcinogenic chemicals.

Socio economic factors &  also serve to play a role in Blood Cancer. Some syndromes that are caused by genetic mutations (abnormal changes) present at birth seem to raise the risk of Blood Cancer.

 

Conferenceseries LLC invites all the participants across the globe to attend the "8th International Conference on Blood Cancer & Treatment” slated on June 26-27, 2017 London, UK.

Theme: Advanced Practices in Blood Cancer Treatment

Dates: June 26-27, 2017

Venue: London, UK.

Blood Cancer & Treatment 2017 conference will be organized by OMICS International along with its subsidiary Conference Series LLC  which is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.

Conference Series LLC is the leading international conference organizer and open access publisher which hosts numerous Cancer Conferences like blood cancer conference, skin cancer conference, breast cancer conference, liver cancer conference, lung cancer meetings, and oncology conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

Why to attend Blood Cancer 2017?

This unique international conference provides a platform for researchers and decision makers in Leukaemia research to present their latest findings and learn about all the important developments in blood cancer research. Many scientists and world's renowned experts will participate in the conference. Throughout the course of the three day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate cancer research communities.

Target Audience

Hematologists

Oncologists

Pathologists

Radiologists

Hematology Associations & Societies

Academicians

Research Scholars

Students

Business Entrepreneurs

Software Developing Companies

Medical Devices Companies

Biomedical Companies

Biotechnology Companies

Data Management Companies

In addition to producing our own oncology meetings, cancer conferences, cancer meetings, oncology conferences  we cooperate with national oncology associations and institutes, cancer leagues and other local groups to ensure the highest academic standards in their programs and to stimulate continuing medical oncology education and training.

Blood cancer is a general term used for the cancers that affect blood, bone marrow or lymphatic system. Most of these cancers start in bone marrow where blood cells (RBC, WBC and platelets) are produced from bone marrow stem cells. There are 4 types of blood cancers such as leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and multiple myeloma.

Importance & Scope

Blood Cancer 2017 will be the best platform for all the haematologists, oncologists, research scholars, students who are working in this field to exchange their knowledge related to Blood Cancer and treatment. This international event is an effort to understand the underlying biological procedures which are amended to increase effectiveness, precision, survivability, and quality of life.

Experts will explain how a new generation of treatment options gives patients new hope in the fight against blood cancer.

Geographically, the global blood cancer treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa .North America takes the largest share of global blood cancer treatment market followed by Europe. The global blood cancer treatment market is expected to grow in future due to increasing investment by multinational companies in cancer research.

            

Why London?

London is the capital and most populous city of England and the United Kingdom with resident population of 7,375, making it the smallest city in England. Standing on the River Thames, London has been a major settlement for two millennia. It’s a city where old and new amiably clash, high culture rubs shoulders with pearly queens – with its streets paved with regal glory.

London is a leading global city, with strengths of heritage, arts, commerce, education, entertainment, fashion, finance, research and development, healthcare, media, professional services and tourism. In UK more than 80 Universities/ colleges, 145 pharmaceutical companies, and more than 60 Associations and societies are working on Hemophilia and other blood related disorders. Funding grants by the government of china for research nearly 200 million USD$ to universities and 1.5 billion USD$ to the pharmaceutical and research institutes.

Conference Highlights:

·         Blood Malignancies

·         Leukemia

·         Myeloma

·         Myelodysplastic Syndrome

·         Childhood Hematological Cancers

·         Blood Cancer Diagnosis

·         Blood Cancer : Causes & Symptoms

·         Blood Cancer : Staging

·         Blood Cancer : Treatment and Care

·         Bone Marrow Transplantation and Surgery

·         Immunology of Blood Cancer

·         Blood Oncology

·         Hematological Malignancies : Prognosis

·         Blood Cancer : Other Aspects

Why to attend..??

This unique international conference provides a platform for researchers and decision makers in cancer research to present their latest findings and learn about all the important developments in cancer research. Many scientists and world's renowned experts will participate in the conference. Throughout the course of the three day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate cancer research communities.

Target Audience

Blood Cancer 2017 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it.

  

Major Associations

In London

Children with Cancer UK

Children’s Cancer and Leukaemia Group

United Kingdom Association of Cancer Registries

Leukemia Cancer Society

Cancer Research UK

Lymphoma Association

Leukaemia & Lymphoma Research

Myeloma UK

Leukaemia CARE

In USA

American Cancer Society (ACS)

Lymphoma Research Foundation, USA

Hematology/Oncology Pharmacy Association

National Cancer Institute

National Children’s Leukaemia Foundation, USA

Cancer Research Institute, USA

International Myeloma Foundation

National Cancer Institute (USA)

Association of International Cancer Research

National Children's Leukemia Foundation

Cancer and Leukemia Group B

International Agency for Research on Cancer (IARC)

Childhood Leukemia Foundation

American Society of Haematology

Union for International Cancer Control (UICC)

Prevent Cancer Foundation

American Childhood Cancer Organisation

American Association for Cancer Research (AACR)

 Worldwide

International Fanconi Anemia Registry (IFAR)

Union for International Cancer Control

The Leukaemia and Lymphoma Society of Canada

Cancer Research UK

Indian Association of blood cancer & Allied Diseases

Leukaemia Cancer Society

Armenian Association of Hematology & Oncology

Leukaemia & Blood Cancer New Zealand

Korean Cancer Association

Fanconi Anaemia Australia

Leukaemia Foundation of Australia

Cancer Association of South Africa

Indian Cancer Society

Brazilian Lymphoma & Leukaemia Association

Chronic Myelogenous Leukaemia Society of Canada

Children’s Cancer and Leukaemia Group

Chinese Society of Clinical Oncology

German Cancer Society

Canadian Cancer Sociey

Lymphoma Foundation Canada

Cancer Society of Finland

France Lymphoma Hope

Society for Paediatric Oncology & Hematology

Leukaemia &Blood Cancer, New Zealand

Medical Oncology Group of Australia

Australian & New Zealand Children’s Hematology/Oncology Group

Childhood Cancer Research Group, UK

National Cancer Institute of Argentina

Cancer Society Nepal

Top Universities

In London

University of Oxford

UCL Medical School

University of Cambridge

King's College London

Queen Mary, University of London

Imperial College, London

Institute on Cancer Research

St. George’s, University of London

The University of Sheffield

In USA

Harvard University

Mayo Medical School, US

Stanford University

Cambridge University

Yale University

University of Colorado

St. George’s University

 Emory University

John Hopkins University

University of Maryland, Baltimore

University of California

North-western University, IIlinois

University of Texas

Massachusetts Institute of Technology (MIT)

Indiana University School of Medicine, Melvin and Bren Simon Cancer Center,

University of Rochester, New York

Carnegie Mellon University, United States of America

University of Pennsylvania, Philadelphia

Cornell University, United States of America

Baylor COLLEGE of medicine US

Princeton University, US

University of Minnesota Medical Center

University of Auckland-

University of Michigan

University of Melbourne

Columbia University, New York

University of Iowa

Ohio State University, Columbus

Rockefeller University, US

 Worldwide

University of Toronto, Canada

Thomas Jefferson University

University of Chicago, Chicago

University of Wisconsin, Madison-

Washington University in St. Louis

University of Tokoyo, Japan

National University of Singapore (NUS), Singapore 

Guangxi Medical University, Nanning, China

Indianapolis University “La Sapienza” of Rome, Rome, Italy 

University of Lyon, France

University Of Leeds 

University Of Queensland,Australia

University of Arizona Cancer Center

University of Utah

Georgetown University Medical Center

 University of Southampton

University of Pittsburgh

 McMaster University

University Of Florida

Vanderbilt University School of Medicine

Wayne State University School of Medicine

University of Alberta

University Of British Columbia 

University Of Leicester 

 University Of Chester

University of Kentucky

University of north Durham

 University Of Surrey

 University Of Edinburgh

 University of Glasgow

 University Of Bordeaux,France

Oregon Health and Science University

 Knight Cancer Institute

Loyola University Chicago

University oF Louisville

 University of Toledo

Rutgers University

University Of Calgary

University Of Witaterstrand

University Of Western Sydney, Australia

University of Melbourne

University Of South Australia

University Of New South Wales

Monash University, Australia

University of Milan, Italy

Kyoto University, Japan

The University of Auckland, NZ

University Of Zurich

National Taiwan University 

The University of Manchester, UK

Ichan School of medicine, Mount Sinai

Pondicherry University, India

University of phoenix

Griffith University

University Of Exeter

Crimea State Medical University,Ukriane

 Heidelberg University

 Hackensack University Medical Center

 Kyoto University, Taiwan

 Osaka University, Japan

 Kursk State Medical University, Russia 

Companies

Roche group is one of the leading providers of blood cancer treatment drugs. Some of the key players in blood cancer treatment market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. To name a few.

Market Analysis report

The market of hematological malignancies is expressed to show steady growth rate during the forecast period from 2014 – 2020. This growth is driven by major factors, such as rising prevalence of various diseases and extensive R&D practices are ongoing across the globe to bring new and more effective drugs and formulations in the market. 

Advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global blood cancer treatment market. However, divergent nature of blood cancers and increasing stringency in the regulatory requirements are some of the major restraints limiting the growth of global blood cancer treatment market.

                     

The global market for Hematological cancer drugs was estimated to be $18.7 billion in 2012.  By 2017, the market is expected to reach $28.8 billion, growing at a CAGR of 9% between 2012 and 2017.The total global market for hematological disorder drugs and diagnostics in 2012 was estimated at nearly $72.9 billion.  By 2017, the market is expected to reach $99.1 billion, growing at a compound annual growth rate (CAGR) of 6.4% between 2012 and 2017.  The global blood disorders market segment is estimated at $49.3 billion in 2012 and is expected to reach nearly $64.7 billion by 2017.  The major reason for the low growth rate is the expected decline in the annual cost of treating blood disorders and the patent expirations of Lovenox, Plavix, Procrit/Epogen, Aranesp, and Neulasta. In 2010, all these drugs together brought revenue of about $32 billion into the global blood disorders market.)

 

Blood Cancer 2016

The success of the Blood Cancer 2016 conference has given us the prospect to bring the gathering one more time. OMICS International along with its subsidiary Conference Series LLC hosted the “4th International Conference on Blood Malignancies & Treatment” during April 18-19, 2016, at The Oberoi, Dubai, UAE

The conference was focused on Blood Cancer and Treatment Research studies with the theme “Conquering blood cancer with contemporary precision therapeutics and restorative approaches”. The meeting engrossed a vicinity of comprehensive discussions on novel subjects like Blood Malignancies, Leukemia, Myeloma, Childhood Hematological Cancers , Blood Cancer : Treatment & Care, Blood Cancer Diagnosis, Blood Cancer : Causes & Symptoms, Bone Marrow Transplantation & Surgery, Blood Cancer : Other Aspects.

The conference was embarked with an opening ceremony followed by Speaker sessions and followed by series of lectures delivered by both Honorable Guests and speakers. The adepts who promulgated the theme with their exquisite talk were:

·         Dr. John Batchelor, Central Manchester Foundation Trust, UK

·         Dr. Jean Jacques Fournié, Cancer Research Center of Toulouse, France

·         Dr. Elena Zakharova, Botkin Memorial Teaching Hospital, Russia

·         Dr. Ashutosh Wechalekar, University College London, UK

·         Dr. Michael Keng, University of Virginia, USA

·         Dr. Inga Mandac Rogulj, Clinical Hospital Merkur, Croatia

 

Best YRF Awardees:

Areeg Bala Elbahsire Moahmed Ahmed: King Abdulaziz Hospital-Al Ahsa, KSA

Talal Hussein Alshareef: King Saud bin Abdulaziz University for Health Sciences, KSA

 

Best Poster Awardees:

Amani Mahbub, Umm Al Qura University, Saudi Arabia

OMICS International offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with OMICS International and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Blood Cancer-2016, OMICS International would like to announce the commencement of the “8thInternational Conference on Blood Cancer & Treatment” to be held during June 26-27, 2017 at London, UK. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Blood Cancer Research.

For More details:  http://bloodmalignancies.conferenceseries.com/

Let us meet again @ Blood Cancer 2017


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 26-27, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
bloodcancer@oncologymeet.com
Sponsors / Exhibiting / Advertising.
bloodcancer@conferenceseries.net
General Queries.
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.